News
Four IDIBELL research groups receive funding from La Marató 3Cat dedicated to cardiovascular diseases
Four IDIBELL research groups receive funding from La Marató 3Cat dedicated to cardiovascular diseases. Ángel Raya, José López, Cristina Enjuanes and Ignasi Anguera are the principal investigators who will carry out the research projects awarded by La Marató 2022.
Bonpreu and Esclat join the fight against diabetes with a fundraising campaign in favor of IDIBELL
During the month of November, customers of this supermarket chain will be able to round up their purchases and collaborate with research against this disease.
Ultra-processed foods, one of the main addictions for children today
14% of adults and 12% of children are addicted to this type of food. Its composition and presentation activate reward neural circuits similarly to alcohol or tobacco.
AELAM donates 15.000€ to research on Lymphangioleiomyomatosis
The association has reached an agreement to undertake a strategic collaboration in order to develop a project to study the biology of glucocorticoids in the origin and evolution of Lymphangioleiomyomatosis.
New study advances the understanding of the resistance mechanisms of ‘Haemophilus parainfluenzae’
This finding, published in the International Journal of Antimicrobial Agents, highlights the possibility that this resistance mechanism could spread to other sexually transmitted pathogens.
IDIBELL joins the “COMBINE” project as an EATRIS Expert Centre to streamline interface between clinical trials, in vitro diagnostics, and medical device investigations
EATRIS, the European Infrastructure for Translational Medicine, has just announced its participation in the stakeholders’ advisory group in the ‘COMBINE’ project, an initiative aimed at providing clarity and alignment at the interface between clinical trials of investigational medicinal products, performance studies of in vitro diagnostics, and clinical investigations of medical devices. COMBINE is an […]
Scientists describe a new biological drug capable of restoring the immune system homeostasis
The IDIBELL research group on immunoinflammatory processes demonstrates that the C4BP (β-) protein could be a promising therapeutic option for inflammatory bowel disease.
Recent findings indicate a promising new therapeutic approach in the fight against cancer, involving a novel combination of treatments
The work has analyzed the interaction of the IKKα protein with these pathways, known for their ability to promote the proliferation of tumor cells. This combination has the advantage of reducing the toxicity of the treatment.
New recommendations for the classification of variants in the POLE and POLD1 genes to improve diagnostic accuracy in hereditary cancer
The group has applied these classification recommendations to 128 variants reported in the literature and/or public databases, classifying 17 as pathogenic variants, and another 17 as benign.